The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally occurring neutralizing antibodies in infected patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with th...
Saved in:
Main Authors: | Sunita S Balla-Jhagjhoorsingh, Davide Corti, Leo Heyndrickx, Elisabeth Willems, Katleen Vereecken, David Davis, Guido Vanham |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/7f92aeb3878d4fa3843e47aaabbfeeb0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Global site-specific N-glycosylation analysis of HIV envelope glycoprotein
by: Liwei Cao, et al.
Published: (2017) -
Alterations in protein expression and site-specific N-glycosylation of prostate cancer tissues
by: Simon Sugár, et al.
Published: (2021) -
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
by: Christopher A. Cottrell, et al.
Published: (2021) -
Site-specific N-glycosylation analysis of animal cell culture-derived Zika virus proteins
by: Alexander Pralow, et al.
Published: (2021) -
Acta Nº276
by: Banco Central de Chile
Published: (2019)